Industry News

• National sickle cell disease poll of african americans dispels long-held views   Pfizer, the NNPA, and Howard University scholars announced results from a new poll designed to deepen understanding and gauge perceptions around sickle cell disease among African Americans. The poll revealed that only one-third were aware that it disproportionately affects people of African descent.
  September 21, 2017  
• New global report finds majority of people at high risk of stroke not being screened  New research by The Economist revealed that on average, more than 75 percent of people aged 65 and older worldwide are not being screened for atrial fibrillation and other common stroke risk factors during routine primary care examinations, even though this population is at high risk.
  September 21, 2017  
• Research ID’s new role of major Alzheimer’s gene  a study led by researchers at Washington University shows that the presence of ApoE4 exacerbates the brain damage caused by toxic tangles of a different Alzheimer’s-associated protein: tau. In the absence of ApoE, tau tangles did very little harm to brain cells.
  September 21, 2017  
• Virginia Tech Carilion Research Institute scientists decode breast cancer protein  Scientists at the Carilion Research Institute have successfully determined the full architecture of the breast cancer susceptibility protein (BRCA1) for the first time. This three-dimensional information provides a potential pathway to restore the BRCA1 protein’s cancer-fighting abilities.
  September 21, 2017  
• SenesTech delivers first sale to natural resources program in Hawaii  SenesTech announced a sales agreement and initial delivery of ContraPest to a Hawaii natural resources program for control of rodents in an outdoor setting under an experimental use permit to control wild rats that prey upon native birds and plants in the preserve.
  September 21, 2017  
• Omadacycline receives Qualified Infectious Disease Product designation from FDA  Paratek announced its investigational antibiotic omadacycline has been granted an additional Qualified Infectious Disease Product designation by the FDA for treatment of uncomplicated urinary tract infections for both the oral and the intravenous formulations.
  September 21, 2017  
• Inovio dMAb™ constructs shrink prostate tumors against antibiotic-resistant infection   Inovio announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers that demonstrate their impact on prostate tumors and in preventing infection from a pneumonia-causing bacteria in preclinical studies.
  September 21, 2017  
• Endologix announces CE Mark approval for Nellix(R) EndoVascular Aneurysm Sealing System  Endologix announced CE Mark approval for its Nellix® EndoVascular Aneurysm Sealing System with refined Indications for Use. Nellix is being studied in the under an IDE. The Company's notified body has determined that Nellix meets applicable safety and clinical performance requirements.
  September 21, 2017  
• Lipocine announces motions decision by USPTO in interference against Clarus  Lipocine announced the USPTO issued a Motions Decision based on each party's motions in the interference case, Patent Interference No. 106,045, between Clarus Therapeutics and Lipocine. The PTAB granted Lipocine's motion to deny Clarus' previously accorded priority date for the ‘428 Patent.
  September 21, 2017  
• Varian announces Penn Medicine treats world's first patient on Halcyon system  Varian announced a patient at Penn Medicine, with head & neck cancer, became the first person in the world to be treated on Varian's Halcyon™ system, its new platform for cancer treatment. The treatment for this patient at Penn Medicine was a complex case that involved the delivery of nine fields.
  September 21, 2017  

   (next 10 articles)